Sign in Subscribe
COVID-19

GSK PLC Secures $370 Million Upfront Payment and Royalties from CureVac Patent Settlement

Strategic Insights

— 1 min read

GSK PLC has reached a significant patent settlement with CureVac, valued at $370 million upfront and 1% royalty on US sales of Pfizer and BioNTech's mRNA vaccines. This deal comes after CureVac and BioNTech settled their mRNA patent litigation in the US, with GSK's entitlement stemming from its licensing partnership with CureVac. The agreement has far-reaching implications, not only securing a substantial payment but also reducing the royalties GSK would owe on its own future mRNA vaccines. Furthermore, GSK stands to gain an additional $130 million in cash and royalties if BioNTech's takeover of CureVac is completed.

Key Takeaways:

  • GSK will receive an upfront payment of $370 million from CureVac as part of a patent settlement involving BioNTech and Pfizer.
  • The deal includes a 1% royalty on US sales of Pfizer and BioNTech's influenza, COVID-19, and related combination mRNA vaccines from 2025.
  • The patent settlement was triggered by the resolution of CureVac and BioNTech's mRNA patent litigation in the US.
  • GSK's entitlement stems from its licensing partnership with CureVac, which has been developing mRNA vaccines as part of its pipeline.
  • The company may receive an additional $130 million in cash and royalties if BioNTech's planned takeover of CureVac is completed.
  • The agreement includes lower future milestone payments and royalties owed on GSK's own mRNA vaccine sales in other markets.
  • GSK will continue its separate litigation against Pfizer and BioNTech in the US and Europe.

Statistics:

  • The upfront payment of $370 million will be booked as other operating income in the third quarter of 2025.
  • GSK stands to gain 1% royalty on US sales of Pfizer and BioNTech's mRNA vaccines.
  • The viability of mRNA vaccines in responding to global health crises like the COVID-19 pandemic has been a major driver of the deal.
  • The settlement is expected to have a positive impact on GSK's financials, but details on the exact impact are yet to be disclosed.
  • mRNA vaccines have played a significant role in the COVID-19 pandemic response, with over [insert number] million doses administered worldwide.

Sources:

  • "GSK PLC (LSE:GSK, NYSE:GSK) ... GSK PLC will receive an upfront payment of $370 million from CureVac..." ["...] (Source: GSK PLC)

Read more